| Stehlik, Josef |
NCT05420012: The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation |
|
|
| Completed | 4 | 26 | US | Vericiguat, VERQUVO, Placebo, Control group | Josef Stehlik, Merck Sharp & Dohme LLC | Heart Failure, Heart Failure with Reduced Ejection Fraction (HFrEF) | 10/24 | 10/24 | | |
NCT06625073: Randomized Trial of SGLT2i in Heart Transplant Recipients |
|
|
| Not yet recruiting | 4 | 200 | US | Empagliflozin, Jardiance, Placebo, Control Group | VA Office of Research and Development | Heart Transplant, Cardiovascular Disease, Kidney Disease | 08/29 | 02/30 | | |
| Active, not recruiting | 2 | 385 | US | tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone | National Institute of Allergy and Infectious Diseases (NIAID), PPD | Heart Transplant | 04/25 | 04/25 | | |
| Withdrawn | N/A | 600 | NA | Prospera Transplant Assessment, Endomyocardial biopsy | Natera, Inc. | Heart Transplant Failure and Rejection | 01/25 | 01/26 | | |
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy |
|
|
| Recruiting | N/A | 250 | US | The Prospera™ Test | Natera, Inc. | Heart Transplant Failure and Rejection | 12/24 | 12/25 | | |
| Completed | N/A | 208 | US | Remote monitoring and predictive analytics, Sham comparator | VA Office of Research and Development, George E. Wahlen Department of Veterans Affairs Medical Center, Michael E. DeBakey VA Medical Center, VA Palo Alto Health Care System, Malcom Randall VA Medical Center, Hunter Holmes McGuire VA Medical Center, VHA Innovation Ecosystem | Heart Failure | 08/24 | 10/24 | | |
NCT02670408: Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation |
|
|
| Recruiting | N/A | 900 | Europe, Canada, US, RoW | Endomyocardial biopsy | University of Alberta | Cardiac Transplant Disorder | 12/25 | 07/26 | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx diagnostic test, Prospera, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Heart Transplant Rejection | 12/26 | 07/27 | | |
DEFINE-HT, NCT05309382: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation |
|
|
| Completed | N/A | 147 | US | Prospera | Natera, Inc. | Heart Transplant | 10/24 | 10/24 | | |
IICAPTAIN-HF, NCT06526988: Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure |
|
|
| Not yet recruiting | N/A | 2200 | US | EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert | University of Colorado, Denver, Patient-Centered Outcomes Research Institute, Yale University, Northwestern University, University of Utah, Sutter Health | Heart Failure With Reduced Ejection Fraction | 09/28 | 09/28 | | |
NCT01099982: Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease |
|
|
| Recruiting | N/A | 300 | US | | University of Utah, Intermountain Health Care, Inc., VA Salt Lake City Health Care System, Hunter Holmes McGuire VA Medical Center | Congestive Heart Failure | 01/28 | 01/28 | | |
